Does Rallies show 13F holders for AKBA?

Yes. Rallies tracks hedge fund and 13F ownership data for AKBA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AKBA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AKBA. It does not provide personalized investment advice.

AKBA (Akebia Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Akebia Therapeutics, Inc. (AKBA) is a publicly traded Healthcare sector company. As of May 21, 2026, AKBA trades at $1.03 with a market cap of $270.94M and a P/E ratio of -12.30. AKBA moved +12.28% today. Year to date, AKBA is -33.11%; over the trailing twelve months it is -65.41%. Its 52-week range spans $0.88 to $4.08. Analyst consensus is strong buy with an average price target of $4.67. Rallies surfaces AKBA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AKBA stock?

Hedge funds tracked by Rallies that own AKBA include Mangrove Partners and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Akebia Therapeutics, Inc..

AKBA Key Metrics

Key financial metrics for AKBA
Metric	Value
Price	$1.03
Market Cap	$270.94M
P/E Ratio	-12.30
EPS	$-0.08
Dividend Yield	0.00%
52-Week High	$4.08
52-Week Low	$0.88
Volume	25.32K
Avg Volume	0
Revenue (TTM)	$232.40M
Net Income	$-20.51M
Gross Margin	81.01%

Top Hedge Funds Holding AKBA

Mangrove Partners holds 375.95K shares of AKBA, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 236.11K shares of AKBA, changed +0.00% as of Mar 31, 2026.

Latest AKBA News

Akebia Q1 Vafseo Sales Hit $15.8M with 60% Patient Growth, FSGS Trial Advances — May 7, 2026
Akebia Therapeutics Doses First Patients in 70-Participant Phase I AKB-9090 Trial — Apr 13, 2026
Akebia to Showcase Phase 2 FSGS, Basket Trials and Phase 1 AKB-9090 on April 2 — Mar 19, 2026
Akebia Reports 49% Revenue Jump to $227M, 290,000 Patients on Vafseo — Feb 26, 2026

Recent AKBA Insider Trades

Butler John P. bought 69.27K (~$86.59K) on Mar 4, 2026.
Malabre Richard C sold 36.14K (~$50.24K) on Feb 2, 2026.
Malabre Richard C sold 13.38K (~$18.60K) on Feb 2, 2026.

AKBA Analyst Consensus

3 analysts cover AKBA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.67.

Common questions about AKBA

Who owns AKBA stock?: Hedge funds tracked by Rallies that own AKBA include Mangrove Partners and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Akebia Therapeutics, Inc..
Does Rallies show 13F holders for AKBA?: Yes. Rallies tracks hedge fund and 13F ownership data for AKBA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AKBA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AKBA. It does not provide personalized investment advice.